Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(±)-Ibipinabant ((±)-SLV319) 是一种有效选择性的大麻素-1 (CB-1) 受体拮抗剂,IC50=22 nM。(±)-SLV319 是 SLV319的消旋体。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 343 | 现货 | ||
2 mg | ¥ 497 | 现货 | ||
5 mg | ¥ 779 | 现货 | ||
10 mg | ¥ 1,360 | 现货 | ||
25 mg | ¥ 2,910 | 现货 | ||
50 mg | ¥ 4,290 | 现货 | ||
100 mg | ¥ 6,130 | 现货 | ||
500 mg | ¥ 12,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 885 | 现货 |
产品描述 | (±)-Ibipinabant ((±)-SLV319) has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes. |
靶点活性 | CB1 :22nM |
体外活性 | Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Ibipinabant is a new, potent [Ki (CB1)=7.8 nM] and selective [Ki (CB2)=7.943 nM] CB1 antagonist [pA2 for arachidonic acid release in CHO cells=9.9] with in vitro pharmacological characteristics similar to rimonabant including inverse agonism and brain penetrance[3]. |
体内活性 | Ibipinabant (3 mg/kg) reduces unfasted glucose to a significantly greater degree than rimonabant at the same dose on days 17, 28 and 38. Chronic treatment with ibipinabant significantly attenuates the progression of diabetes in ZDF rats, blunting the increase in blood glucose and HbA1c over time. Ibipinabant also reduces the hyperinsulinemia apparent at 6-8 weeks of age and attenuates the dramatic reduction in insulin levels observed 1-2 weeks later[3]. |
动物实验 | Rats: SLV319, rimonabant and rosiglitazone are suspended in a 10% dimethylacetamide, 10% cremophor, 10% ethanol and 70% water vehicle. Drugs are administered by oral gavage in a volume of 2 mL/kg body weight at 09:00 hours every day. Treatment groups are as follows: (i) Vehicle: ad libitum access to food (vehicle), (ii) Vehicle: restricted access to food (20% less than average food intake of ad libitum vehicle-treated group for the first 3 days of the study, then 10% less than the average food intake of the ad libitum vehicle-treated group for the remainder of the study) (restricted), (iii) Rosiglitazone (4 mg/kg), (iv) Rimonabant (3 mg/kg) (RIM 3 mg/kg), (v) Rimonabant (10 mg/kg) (RIM 10 mg/kg), (vi) SLV319 (3 mg/kg) (IBI 3 mg/kg) and (vii) Ibipinabant (10 mg/kg) (IBI 10 mg/kg). Rosiglitazone is used as a positive control for its ability to delay β-cell decline, and rimonabant is used as a positive control for CB1 antagonism[3]. |
别名 | (±)-BMS6462, SLV319, (±)-SLV319 |
分子量 | 487.4 |
分子式 | C23H20Cl2N4O2S |
CAS No. | 362519-49-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (92.33 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0517 mL | 10.2585 mL | 20.517 mL | 51.2926 mL |
5 mM | 0.4103 mL | 2.0517 mL | 4.1034 mL | 10.2585 mL | |
10 mM | 0.2052 mL | 1.0259 mL | 2.0517 mL | 5.1293 mL | |
20 mM | 0.1026 mL | 0.5129 mL | 1.0259 mL | 2.5646 mL | |
50 mM | 0.041 mL | 0.2052 mL | 0.4103 mL | 1.0259 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(±)-Ibipinabant 362519-49-1 GPCR/G Protein Cannabinoid Receptor SLV 319 Inhibitor BMS6462 (±)-BMS6462 SLV-319 BMS 6462 (±) Ibipinabant BMS-6462 Ibipinabant SLV319 inhibit (±)Ibipinabant (±)-SLV319 inhibitor